Fintech & Payments

How Is This Fintech Startup Using Visa to Bring Crypto Into Everyday Payments?

Inside Mercuryo’s Visa Partnership

Updated

January 29, 2026 1:34 PM

Close up of Visa credit cards. PHOTO: ADOBE STOCK

Mercuryo is a fintech startup that builds the infrastructure to enable money to move seamlessly between crypto and traditional banking systems. In simple terms, it works on the problem of turning digital assets into usable cash.

As more people hold crypto through wallets and exchanges, one practical issue keeps arising: how do you actually withdraw that money and use it in the real world? For many users, converting tokens into local currency is still slow, confusing or expensive. That gap between “owning” crypto and being able to spend it is where Mercuryo operates.

The company’s latest step forward is a partnership with Visa to improve what is known as “off-ramping” — the process of converting crypto into fiat currency like dollars or euros. Until now, this has often been slow, expensive and confusing for users. Mercuryo is using Visa Direct, Visa’s real-time payments system, to make that process faster and more direct.

With this integration, users can convert their digital tokens into local currency and send the money straight to a Visa debit or credit card. The transaction happens through systems that already power global card payments, which means the money can arrive in near real time instead of days later.

Technically, this connects two very different worlds. On one side is blockchain-based crypto, which moves value on decentralised networks. On the other side is the traditional payment system, which runs on banks, cards and regulated rails. Mercuryo’s platform sits between the two and handles the conversion and movement of funds.

Instead of users leaving their wallet or exchange to cash out, Mercuryo allows the conversion to happen inside the apps and platforms they already use. The user does not need to understand the plumbing behind it. They just see that crypto becomes spendable money on their card.

This matters because access is what makes any financial system usable. If people cannot easily move their money, they treat it as locked or risky. Faster off-ramps make digital assets more practical, not just speculative.

Mercuryo’s work is not about creating new tokens or trading tools. It is about building the pipes that let money move smoothly between Web3 and the traditional financial world. The Visa partnership strengthens those pipes by using a global, trusted payments network that already works at scale.

Visa also framed the partnership as a bridge between systems. Anastasia Serikova, Head of Visa Direct, Europe, said: "By leveraging Visa Direct's capabilities, Mercuryo is not only making converting to fiat faster, simpler and more accessible than ever—it's building bridges between the crypto space and the traditional financial system. This integration empowers users to seamlessly convert digital assets into fiat in near real time, creating a more connected and convenient payment experience".

Over time, this kind of infrastructure is what determines whether crypto remains niche or becomes part of everyday finance. Not through headlines, but through systems that quietly reduce friction.

Mercuryo’s direction is clear: make digital assets easier to use, easier to exit and easier to connect to the money systems people already rely on.

Keep Reading

Health & Biotech

OpenAI and Top Investors Back Valthos with US$30M to Advance AI-Driven Biodefense

Reimagining biodefense at the intersection of AI, biology and urgency.

Updated

January 8, 2026 6:34 PM

Through computational tools, Valthos analyzes biological data to design adaptive solutions against emerging threats. PHOTO: VALTHOS

Valthos has raised US$30 million in seed funding, led by the OpenAI Startup Fund, Lux Capital and Founders Fund, to advance its mission of building next-generation biodefense systems.

The company’s work comes at a time when biotechnology is evolving at an unprecedented pace. Biotechnology is moving at record speed. These new tools can lead to life-changing medical discoveries, but they also bring the risk of dangerous biological agents being developed faster than ever.  

“The issue at the core of biodefense is asymmetry”, said Kathleen McMahon, co-founder of Valthos. “It’s easier to make a pathogen than a cure. We’re building tools to help experts at the frontlines of biodefense move as fast as the threats they face”. The gap Valthos aims to close is between the rapid rise of biological threats and the slower pace of developing cures. Therefore, the company is developing AI systems that can rapidly analyze biological sequences and significantly shorten the time needed to design medical countermeasures.

“In this new world, the only way forward is to be faster. So we set out to build a new tech stack for biodefense”, said Tess van Stekelenburg, co-founder of Valthos. “This software infrastructure strengthens biodefense today and lays the groundwork for the adaptive, precision therapeutics of tomorrow”.

The company was founded by van Stekelenburg, a partner at Lux Capital and McMahon, the former head of Palantir’s Life Sciences division. Together, they’ve built a multidisciplinary team of experts from Palantir, DeepMind, Stanford’s Arc Institute and MIT’s Broad Institute, bringing together deep experience in software engineering, machine learning and biotechnology.

“Technology is moving fast. An industrial ecosystem of builders, companies and solutions further democratizes AI to provide broad resilience, and ensures the U.S. continues to lead as AI increasingly powers everything around us. As AI and biotech rapidly advance, biodefense is one of the new industry verticals that helps maximize the benefits and minimize the risks”, said Jason Kwon, OpenAI’s Chief Strategy Officer. “Valthos is pushing the frontier of protection and defense in one of the most strategic intersections of multiple world-changing technologies, and with the team to do it”.

Looking ahead, Valthos plans to expand its engineering team and scale its software infrastructure for both government and commercial partners — moving closer to its goal of enabling faster, smarter and more adaptive biodefense capabilities.